CN103966263A - 一种重组人3型腺病毒及其制备方法和应用 - Google Patents
一种重组人3型腺病毒及其制备方法和应用 Download PDFInfo
- Publication number
- CN103966263A CN103966263A CN201310043885.9A CN201310043885A CN103966263A CN 103966263 A CN103966263 A CN 103966263A CN 201310043885 A CN201310043885 A CN 201310043885A CN 103966263 A CN103966263 A CN 103966263A
- Authority
- CN
- China
- Prior art keywords
- human adenovirus
- region
- recombinant human
- hexon
- adenovirus type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193096 Human adenovirus B3 Species 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 241001529459 Enterovirus A71 Species 0.000 claims abstract description 52
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 27
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 14
- 101710197658 Capsid protein VP1 Proteins 0.000 claims abstract description 14
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims abstract description 14
- 101710108545 Viral protein 1 Proteins 0.000 claims abstract description 14
- 229940031416 bivalent vaccine Drugs 0.000 claims abstract description 4
- 239000013598 vector Substances 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 claims description 10
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000006386 neutralization reaction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 241000598171 Human adenovirus sp. Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 241000709661 Enterovirus Species 0.000 abstract description 4
- 229940125575 vaccine candidate Drugs 0.000 abstract description 4
- 206010021432 Immunisation reaction Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 32
- 241000701161 unidentified adenovirus Species 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000000234 capsid Anatomy 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000001976 enzyme digestion Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000010276 construction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101710094396 Hexon protein Proteins 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229940021704 adenovirus vaccine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101150024766 VP1 gene Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008349 antigen-specific humoral response Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310043885.9A CN103966263A (zh) | 2013-02-04 | 2013-02-04 | 一种重组人3型腺病毒及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310043885.9A CN103966263A (zh) | 2013-02-04 | 2013-02-04 | 一种重组人3型腺病毒及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103966263A true CN103966263A (zh) | 2014-08-06 |
Family
ID=51236267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310043885.9A Pending CN103966263A (zh) | 2013-02-04 | 2013-02-04 | 一种重组人3型腺病毒及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966263A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105219740A (zh) * | 2015-09-29 | 2016-01-06 | 东莞市第八人民医院 | 一种重组人3型腺病毒及制备方法和应用 |
CN105238766A (zh) * | 2015-10-15 | 2016-01-13 | 东莞市第八人民医院 | 人3型腺病毒展示人14型腺病毒中和抗原表位疫苗候选株的制备方法和应用 |
CN105238767A (zh) * | 2015-10-15 | 2016-01-13 | 东莞市第八人民医院 | 人3型腺病毒展示人55型腺病毒中和抗原表位疫苗候选株的制备方法和应用 |
CN106220738A (zh) * | 2016-07-31 | 2016-12-14 | 中国医学科学院医学生物学研究所 | Ev71中和抗原表位与诺如病毒p结构域嵌合载体的构建和表达方法 |
CN106754760A (zh) * | 2017-01-20 | 2017-05-31 | 华南农业大学 | 一种嵌合ibdv中和表位的重组人3型腺病毒的制备方法和应用 |
CN110283795A (zh) * | 2019-05-30 | 2019-09-27 | 广州市妇女儿童医疗中心 | 同时展示ev71病毒和cva16病毒中和抗原表位的重组腺病毒 |
CN110699380A (zh) * | 2019-09-04 | 2020-01-17 | 广州医科大学附属第一医院 | 一种ev71病毒核酸质粒及其构建方法及应用 |
CN111108192A (zh) * | 2017-07-05 | 2020-05-05 | Nouscom股份公司 | 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途 |
-
2013
- 2013-02-04 CN CN201310043885.9A patent/CN103966263A/zh active Pending
Non-Patent Citations (5)
Title |
---|
C. WU等: "Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus", 《VACCINE》 * |
D. FOO等: "Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides", 《VIRUS RESEARCH》 * |
GONG S.等: "登录号:FJ360545.1", 《GENBANK》 * |
X. TIAN等: "Protection against Enterovirus 71 with Neutralizing Epitope Incorporation within Adenovirus Type 3 Hexon", 《PLOS ONE》 * |
唐启慧等: "肠道病毒71型衣壳蛋白VP1基因部分序列在大肠杆菌中的表达", 《热带医学杂志》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105219740A (zh) * | 2015-09-29 | 2016-01-06 | 东莞市第八人民医院 | 一种重组人3型腺病毒及制备方法和应用 |
CN105238766A (zh) * | 2015-10-15 | 2016-01-13 | 东莞市第八人民医院 | 人3型腺病毒展示人14型腺病毒中和抗原表位疫苗候选株的制备方法和应用 |
CN105238767A (zh) * | 2015-10-15 | 2016-01-13 | 东莞市第八人民医院 | 人3型腺病毒展示人55型腺病毒中和抗原表位疫苗候选株的制备方法和应用 |
CN105238767B (zh) * | 2015-10-15 | 2018-10-19 | 东莞市第八人民医院 | 人3型腺病毒展示人55型腺病毒中和抗原表位疫苗候选株的制备方法和应用 |
CN105238766B (zh) * | 2015-10-15 | 2018-10-19 | 东莞市第八人民医院 | 人3型腺病毒展示人14型腺病毒中和抗原表位疫苗候选株的制备方法和应用 |
CN106220738A (zh) * | 2016-07-31 | 2016-12-14 | 中国医学科学院医学生物学研究所 | Ev71中和抗原表位与诺如病毒p结构域嵌合载体的构建和表达方法 |
CN106754760A (zh) * | 2017-01-20 | 2017-05-31 | 华南农业大学 | 一种嵌合ibdv中和表位的重组人3型腺病毒的制备方法和应用 |
CN111108192A (zh) * | 2017-07-05 | 2020-05-05 | Nouscom股份公司 | 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途 |
CN111108192B (zh) * | 2017-07-05 | 2023-12-15 | Nouscom股份公司 | 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途 |
CN110283795A (zh) * | 2019-05-30 | 2019-09-27 | 广州市妇女儿童医疗中心 | 同时展示ev71病毒和cva16病毒中和抗原表位的重组腺病毒 |
CN110699380A (zh) * | 2019-09-04 | 2020-01-17 | 广州医科大学附属第一医院 | 一种ev71病毒核酸质粒及其构建方法及应用 |
CN110699380B (zh) * | 2019-09-04 | 2023-12-15 | 广州医科大学附属第一医院 | 一种ev71病毒核酸质粒及其构建方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111218459B (zh) | 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗 | |
JP7285833B2 (ja) | アデノウイルス及びその用途 | |
CN103966263A (zh) | 一种重组人3型腺病毒及其制备方法和应用 | |
JP7229239B2 (ja) | アデノウイルスベクター及びその用途 | |
Gall et al. | Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype | |
JP2021500908A (ja) | アデノウイルス及びその用途 | |
Koho et al. | Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice | |
WO2022218325A1 (zh) | 一种基因缺失的减毒非洲猪瘟病毒毒株及其构建方法和应用 | |
CN103555746B (zh) | 重组猪圆环病毒2型病毒样粒子及其制备方法和应用 | |
WO2022007742A1 (zh) | 一种重组的伪狂犬病病毒及其疫苗组合物 | |
WO2021139147A1 (zh) | 一种腺病毒二价疫苗 | |
TW201602347A (zh) | 對抗腸病毒感染之基於腺病毒載體之疫苗 | |
Dus Santos et al. | Transgenic plants for the production of veterinary vaccines | |
CN110616199A (zh) | 一种复制缺陷型重组人7型腺病毒及其制备方法和应用 | |
CN105802923B (zh) | 一种重组脊髓灰质炎病毒样颗粒及其制备方法与应用 | |
CN103555680A (zh) | 一种具有免疫原性的prrsv病毒样颗粒及其制备与应用 | |
WO2015024484A1 (zh) | 一种新型狂犬病疫苗及其制备方法 | |
Ryding et al. | Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles | |
CN105238766B (zh) | 人3型腺病毒展示人14型腺病毒中和抗原表位疫苗候选株的制备方法和应用 | |
CN105238767B (zh) | 人3型腺病毒展示人55型腺病毒中和抗原表位疫苗候选株的制备方法和应用 | |
CN103865923B (zh) | 流感病毒为载体的HAdV嵌合疫苗的制备及其应用 | |
Guo et al. | Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice | |
Xie et al. | Adenovirus-vectored capsid proteins of the serotype a foot-and-mouth disease virus protect guinea pigs against challenge | |
Li et al. | A recombinant capripoxvirus expressing the F protein of peste des petits ruminants virus and the P12A3C of foot-and-mouth disease virus | |
Ziraldo et al. | Optimized adenoviral vector that enhances the assembly of fmdv o1 virus-like particles in situ increases its potential as vaccine for serotype o viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 510120 Yuexiu District, Guangdong Province along the Yangtze River Road, No. 151, No. Applicant after: the First Affiliated Hospital of Guangzhou Medical University Applicant after: Guangzhou Institute of Respiratory Disease Address before: 510120 Yuexiu District, Guangdong Province along the Yangtze River Road, No. 151, No. Applicant before: The Second Affiliated Hospital of Guangzhou Medical School Applicant before: Guangzhou Institute of Respiratory Disease |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL SCHOOL TO: FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY |
|
DD01 | Delivery of document by public notice |
Addressee: Rao Yang Document name: Notification of Passing Examination on Formalities |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140806 |
|
WD01 | Invention patent application deemed withdrawn after publication |